Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Strategic Asset Allocation Index
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd strategic asset allocation index. Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a Strategic Asset Allocation Index of 26.7% as of June 2023. Strategic assets (PP&E of CN¥574.79 Million plus long-term investments of CN¥-) total CN¥574.79 Million, measured against net assets of CN¥2.15 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Zhejiang Wolwo Bio-Pharmaceutical Co Ltd net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2010–2022)
Strategic asset allocation index of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2010 to 2022. This chart shows how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's Strategic Asset Allocation Index has evolved across 13 annual periods from 2010 to 2022. As of June 2023, the index stands at 26.7%, representing strategic assets of CN¥574.79 Million against net assets of CN¥2.15 Billion CNY. Check tangible net worth ratio of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Strategic Asset Allocation Index by Year (2010–2022)
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd strategic asset allocation index by year from 2010 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2010 to 2022, covering 13 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300357 stock market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 21.9% | CN¥444.61 Million | CN¥444.61 Million | CN¥- | CN¥2.03 Billion | ▲ +5.1 pp |
| 2021 | 16.8% | CN¥301.62 Million | CN¥301.62 Million | CN¥- | CN¥1.80 Billion | ▲ +1.1 pp |
| 2020 | 15.7% | CN¥240.16 Million | CN¥240.16 Million | CN¥- | CN¥1.53 Billion | ▲ +1.1 pp |
| 2019 | 14.6% | CN¥197.63 Million | CN¥197.63 Million | CN¥- | CN¥1.35 Billion | ▼ -0.5 pp |
| 2018 | 15.1% | CN¥150.68 Million | CN¥137.68 Million | CN¥13.00 Million | CN¥995.42 Million | ▼ -1.9 pp |
| 2017 | 17.0% | CN¥136.56 Million | CN¥123.56 Million | CN¥13.00 Million | CN¥801.26 Million | ▼ -1.0 pp |
| 2016 | 18.1% | CN¥118.53 Million | CN¥118.53 Million | CN¥- | CN¥655.58 Million | ▲ +1.4 pp |
| 2015 | 16.6% | CN¥96.97 Million | CN¥96.97 Million | CN¥- | CN¥582.91 Million | ▲ +4.9 pp |
| 2014 | 11.7% | CN¥60.28 Million | CN¥60.28 Million | CN¥- | CN¥513.55 Million | ▼ -9.4 pp |
| 2013 | 21.1% | CN¥53.18 Million | CN¥53.18 Million | CN¥- | CN¥251.92 Million | ▼ -2.9 pp |
| 2012 | 24.0% | CN¥43.60 Million | CN¥43.60 Million | CN¥- | CN¥181.38 Million | ▼ -8.6 pp |
| 2011 | 32.6% | CN¥41.60 Million | CN¥41.60 Million | CN¥- | CN¥127.61 Million | ▼ -15.7 pp |
| 2010 | 48.3% | CN¥43.73 Million | CN¥43.73 Million | CN¥- | CN¥90.44 Million | — |